206361-99-1
  • Air Pro206361-99-1

206361-99-1

We have more than 10 years of experience in custom synthesis of compounds. If you are looking for a supplier or manufacturer of Darunavir (CAS No.: 206361-99-1) please contact us. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Darunavir (CAS No.: 206361-99-1) and other compounds. We can provide high-quality compounds and good service fou you.

Send Inquiry

Product Description

Name

Darunavir

Synonyms

TMC-114;Darunavir;(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate

Molecular Formula

C27H37N3O7S

Molecular Weight

547.66400

CAS Number

206361-99-1

purity

97%

Storage conditions

Keep in dark place,Sealed in dry,Store in freezer,under -20°C










Application:Darunavir (brand name Prezista, formerly known as TMC114) (CAS No.: 206361-99-1) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents.
Darunavir is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Early PIs often have severe side effects and drug toxicities, require a high therapeutic dose, are costly to manufacture, and show a disturbing susceptibility to drug resistant mutations. Such mutations can develop in as little as a year of use, and effectively render the drugs useless.
Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs.
It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Developed by pharmaceutical company Tibotec, darunavir is named after Arun K. Ghosh, the chemistry professor who discovered the molecule at the University of Illinois at Chicago. It was approved by the Food and Drug Administration (FDA) on June 23, 2006. Darunavir received attention at the time of its release, as it represents a treatment option for people with drug-resistant HIV. Patient advocacy groups pressured developer Tibotec not to follow the previous trend of releasing new drugs at prices higher than existing drugs in the same class. Darunavir was priced to match other common PIs already in use, such as the fixed-dose combination drug lopinavir/ritonavir. The drug costs around $9,000 for a one-year supply.



Hot Tags: 206361-99-1,Innovative Drugs, Pharmaceutical Intermediates, API, Custom Synthesis, Chemical Custom Synthesis, Research Chemicals, Materials Science Intermediates, Catalysts and Ligands, Organometallic Catalysts, Anticancer Drugs, Leucemia, Inhibitors, Flame Retardants, Ultraviolet Absorbers, Antioxidants, Photosensitizers, PhotoInitiators

Related Category

Send Inquiry

Please feel free to give your inquiry in the form below. We will reply you within 24 hours.